News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
275,307 Results
Type
Article (15011)
Company Profile (296)
Press Release (260000)
Section
Business (83181)
Career Advice (158)
Deals (13758)
Drug Delivery (36)
Drug Development (51267)
Employer Resources (32)
FDA (6084)
Job Trends (5465)
News (150101)
Policy (10564)
Tag
Academia (977)
Alliances (22699)
Alzheimer's disease (748)
Approvals (6058)
Artificial intelligence (64)
Bankruptcy (101)
Best Places to Work (4793)
Biotechnology (243)
Breast cancer (67)
Cancer (711)
Cardiovascular disease (65)
Career advice (139)
CAR-T (58)
Cell therapy (181)
Clinical research (40593)
Collaboration (246)
Compensation (101)
COVID-19 (1044)
C-suite (68)
Cystic fibrosis (67)
Data (816)
Diabetes (73)
Diagnostics (1365)
Earnings (30227)
Events (48971)
Executive appointments (196)
FDA (6385)
Funding (258)
Gene editing (55)
Gene therapy (149)
GLP-1 (310)
Government (1138)
Healthcare (7012)
Infectious disease (1080)
Inflammatory bowel disease (95)
IPO (7401)
Job creations (919)
Job search strategy (134)
Layoffs (191)
Legal (1501)
Lung cancer (115)
Manufacturing (76)
Medical device (3158)
Medtech (3159)
Mergers & acquisitions (6462)
Metabolic disorders (229)
Neuroscience (964)
NextGen Class of 2024 (2218)
Non-profit (953)
Northern California (976)
Obesity (128)
Opinion (95)
Parkinson's disease (62)
Patents (52)
People (26012)
Pharmaceutical (50)
Phase I (14196)
Phase II (18854)
Phase III (12054)
Pipeline (338)
Postmarket research (875)
Preclinical (6021)
Radiopharmaceuticals (209)
Rare diseases (172)
Real estate (1524)
Regulatory (8577)
Research institute (989)
Southern California (890)
Startups (2009)
United States (7856)
Vaccines (170)
Weight loss (80)
Date
Today (27)
Last 7 days (424)
Last 30 days (2286)
Last 365 days (21390)
2024 (19654)
2023 (23274)
2022 (28086)
2021 (29147)
2020 (24768)
2019 (17782)
2018 (12922)
2017 (14622)
2016 (12617)
2015 (15161)
2014 (10932)
2013 (7985)
2012 (8056)
2011 (8172)
2010 (7826)
Location
Africa (158)
Asia (17418)
Australia (2955)
California (2213)
Canada (728)
China (173)
Colorado (84)
Connecticut (90)
Europe (37983)
Florida (248)
Georgia (72)
Illinois (132)
Indiana (57)
Kansas (56)
Maryland (307)
Massachusetts (1746)
Michigan (50)
Minnesota (98)
New Jersey (559)
New York (629)
North Carolina (404)
Northern California (976)
Ohio (82)
Pennsylvania (436)
South America (223)
Southern California (890)
Texas (233)
Washington State (223)
275,307 Results for "io therapeutics".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Press Releases
IO Biotech Reports its Off-the-Shelf Therapeutic Cancer Vaccine, IO102-IO103, in Combination with KEYTRUDA® Demonstrates Promising Activity and Durability in First-line Treatment of Patients with Metastatic Lung Cancer in Phase 2 IOB-022 Study
November 8, 2024
·
9 min read
Pharm Country
IO Biotech Presents New Data at AACR 2024 Further Supporting Dual Mechanism of Action of Lead Cancer Vaccine, IO102-IO103
IO Biotech, a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, shared new data related to the company’s lead therapeutic cancer vaccine candidate, IO102-IO103, at the American Association for Cancer Research Annual Meeting 2024, taking place April 5-10, 2024, in San Diego, California.
April 9, 2024
·
5 min read
Press Releases
IO Biotech Announces Participation in Upcoming Investor Conferences
November 12, 2024
·
3 min read
Press Releases
Akoya Biosciences Unveils a New Era in Spatial Content Innovation with the PhenoCode™ Discovery IO60 and Mouse FFPE IO Panel
November 6, 2024
·
6 min read
Press Releases
IO Biotech Announces Positive Results from Phase 2 Trial of IO102-IO103 in the First-line Treatment of Advanced Head and Neck Cancer
September 16, 2024
·
7 min read
Drug Development
IO Biotech Expands Senior Leadership Team to Progress Commercialization Readiness
IO Biotech today announced that Marjan Shamsaei, PharmD, joined the company as SVP, Commercial Development and Portfolio Lead for IO102-IO103, the company’s lead cancer vaccine candidate currently in a pivotal Phase 3 trial.
April 15, 2024
·
4 min read
Pharm Country
IO Biotech Announces Abstract Accepted for Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
IO Biotech (Nasdaq: IOBT) today announced the acceptance of an abstract related to IO102-IO103, the company’s lead investigational therapeutic cancer vaccine candidate, for presentation at the American Society of Clinical Oncology (ASCO) Annual Meeting, taking place in Chicago May 31-June 4, 2024.
April 24, 2024
·
5 min read
Press Releases
IO Biotech Updates on Pivotal Phase 3 Trial of IO102-IO103 in Combination with KEYTRUDA® (pembrolizumab) as a First-Line Treatment for Patients with Advanced Melanoma
September 2, 2024
·
8 min read
Business
IO Biotech Reports First Quarter 2024 Financial Results and Provides Business Highlights
IO Biotech (Nasdaq: IOBT), a clinical-stage biopharmaceutical company developing novel, immune-modulating therapeutic cancer vaccines based on its T-win® platform, today reported financial results for the first quarter ended March 31, 2024.
May 14, 2024
·
14 min read
Pharm Country
IO Biotech to Present at Jefferies Global Healthcare Conference
IO Biotech announced today that Mai-Britt Zocca, Ph.D., the company’s President and CEO, will be presenting, and both Dr. Zocca and Amy Sullivan, the company’s CFO, will be participating in one-on-one investor meetings at the Jefferies Global Healthcare Conference to be held June 4-6, 2024 in New York.
May 23, 2024
·
3 min read
1 of 27,531
Next
